Hepatitis C Therapy - Schering-Plough Corporation (SGP)'s Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity As Mono

Schering-Plough Corporation (SGP)'s Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity As Mono
BioSpace - Schering-Plough Corporation (SGP)'s Oral HCV Protease Inhibitor Demonstrates Potent Antiviral Activity As Monotherapy And In Combination With PEG-INTRON(R) In Phase I Studies SAN FRANCISCO, Nov. infected with hepatitis C virus (HCV) genotype 1 who were nonresponders to

ViroPharma to Host Conference Call to Discuss Clinical Results of HCV-796
Primezone Media Network - Incorporated ViroPharma to Host Conference Call to Discuss Clinical Results of HCV-796 EXTON, Pa Phase 1b study with HCV-796, an orally dosed hepatitis C (HCV) viral polymerase

MIGENIX initiates enrolment in Phase IIb HCV study of celgosivir+Pegetron
InPharm.com - Celgosivir is a first-in-class, orally-administered, alpha glucosidase 1 inhibitor in development for the treatment of chronic hepatitis C (HCV) infections. Results of the study are anticipated in mid-2006.

Five Million Americans Infected with the Hepatitis C Virus: A Corrected Estimate
National AIDS Treatment Advocacy Project - 4 million persons ( a million) have antibody to HCV, so have ever been infected, and about 3 million have HCV RNA, so currently remain infected